ArticleMuscle & nerve2020
Amyotrophic lateral sclerosis care and research in the United States during the COVID-19 pandemic: Challenges and opportunities.
Article in Muscle & nerve, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 59 citations in OpenAlex.
- Approaching Serious Illness Conversations in Amyotrophic Lateral Sclerosis Using Telehealth: A Practical Guide.Neurology. Clinical practice · 2026Review
- The Amyotrophic Lateral Sclerosis House Call Program: A Single-Center Experience in the United States.Neurology research international · 2026Article
- Short-term ambient temperature increases are associated with higher mortality in amyotrophic lateral sclerosis: a case-crossover study of weather conditions.Frontiers in aging neuroscience · 2026Article
- ALS Motor Observational Telemedicine Objective Rasch-Built Assessment: A Quantitative Scale for the Era of Teleneurology.Neurology. Clinical practice · 2025Article
- Working with people living with motor neurone disease and the impact on professionals' emotional and psychological well-being: A scoping review.Palliative medicine · 2025Article
- Impact of SARS-CoV-2 infection and COVID-19 pandemic on the morbidity and mortality of amyotrophic lateral sclerosis patients in Valencia, Spain.European journal of neurology · 2024Article
- Enhancing ALS disease management: exploring integrated user value through online communities evidence.Frontiers in neurology · 2024Article
- Asynchronous online focus groups for research with people living with amyotrophic lateral sclerosis and family caregivers: usefulness, acceptability and lessons learned.BMC medical research methodology · 2023Article
- Amyotrophic Lateral Sclerosis and Its Management during the COVID-19 Pandemic: A Qualitative Study with Thematic Analysis of Patients and Caregivers Who Participated in Self-Help Groups.Behavioral sciences (Basel, Switzerland) · 2023Article
- Pulmonary care for ALS: Progress, gaps, and paths forward.Muscle & nerve · 2023Review
- Telehealth for amyotrophic lateral sclerosis in a multidisciplinary service in a Brazilian reference center.Arquivos de neuro-psiquiatria · 2023Article
- Delivery of noninvasive ventilation to people living with motor neuron disease in the UK.ERJ open research · 2023Article
- Life Experiences in Neuromuscular Tracheotomized Patients in Times of Covid-19.Journal of neuromuscular diseases · 2023Article
- Considerations for Amyotrophic Lateral Sclerosis (ALS) Clinical Trial Design.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2022Review
- Covid-19 threat and coping: application of protection motivation theory to the pandemic experiences of people affected by amyotrophic lateral sclerosis.BMC neurology · 2022Article
- A Road Map for Remote Digital Health Technology for Motor Neuron Disease.Journal of medical Internet research · 2021Article
- Article
- Telehealth in Neurodegenerative Diseases: Opportunities and Challenges for Patients and Physicians.Brain sciences · 2021Review
- COVID-19 and the neurological disease therapeutic pipeline.Nature reviews. Neurology · 2021Review
- Impact of COVID-19 on people with physical disabilities: A rapid review.Disability and health journal · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 10 institutions in 1 country.
Funding
Abstract
Coronavirus disease 2019 has created unprecedented challenges for amyotrophic lateral sclerosis (ALS) clinical care and research in the United States. Traditional evaluations for making an ALS diagnosis, measuring progression, and planning interventions rely on in-person visits that may now be unsafe or impossible. Evidence- and experience-based treatment options, such as multidisciplinary team care, feeding tubes, wheelchairs, home health, and hospice, have become more difficult to obtain and in some places are unavailable. In addition, the pandemic has impacted ALS clinical trials by impairing the ability to obtain measurements for trial eligibility, to monitor safety and efficacy outcomes, and to dispense study drug, as these also often rely on in-person visits. We review opportunities for overcoming some of these challenges through telemedicine and novel measurements. These can reoptimize ALS care and research in the current setting and during future events that may limit travel and face-to-face interactions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.